FogPharma is developing a new class of drugs to address the limitations of today’s precision medicines and achieve universal druggability. The company is pioneering the discovery, development and commercialization of HeliconTM peptides, a new drug modality that uniquely combines the broad targeting power of monoclonal antibodies with the cell-penetrating ability of small molecules. HeliconTM peptides hold the promise, not only to drug nearly all human disease drivers, but also to do so with unrivaled speed and scalability.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $496M
Founded date: 2016
Investors 6
| Date | Name | Website |
| 08.11.2023 | ARCH Ventu... | archventur... |
| - | 6 Dimensio... | 6dimension... |
| - | HBM Partne... | hbmpartner... |
| 19.03.2024 | Catalio Ca... | cataliocap... |
| 16.08.2024 | SymBiosis | symbiosis.... |
| - | GV | gv.com |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 03.03.2024 | Series E | $145M | - |
| 27.11.2022 | Series D | $178M | - |
| 02.03.2021 | Series C | $107M | - |
| 21.05.2018 | Series B | $66M | - |
Mentions in press and media 14
| Date | Title | Description |
| 03.03.2024 | FogPharma Raises $145M Financing | FogPharma, a Cambridge, MA-based clinical-stage biopharmaceutical company, raised $145M in Series E funding. The round was led by Nextech Invest with participation from other new investors including RA Capital Management, Rock Springs Capit... |
| 01.03.2024 | FogPharma clears $145M series E thanks to Alexis Borisy, ex-J&J CEO Alex Gorsky | We all aspire to have a boss who will just give you money for your next endeavor. Mathai Mammen, M.D., Ph.D., happens to have just that. Johnson & Johnson’s former pharma R&D chief, now the CEO of FogPharma, has brought on former J&... |
| 27.11.2022 | FogPharma’s $178M Funding Leads Way as 7 Biotechs Raise Cash for Cancer Drugs | Cancer continues to be a big draw for biotech investors, and cancer research is well represented in the past week’s financing activity. Seven biotech companies announced financing rounds to support a range of tumor-targeting therapeutic app... |
| 22.11.2022 | FogPharma Raises $178M in Series D Financing | FogPharma, a Cambridge, MA-based biopharmaceutical company, raised $178M in Series D funding. The round includes new investors ARCH Venture Partners, Milky Way Investments, Fidelity Management & Research Company, and existing investors ... |
| 21.11.2022 | FogPharma Announces $178M Series D Financing | CAMBRIDGE, MA, FogPharma, a biopharmaceutical company, announced a $178 Million Series D financing. >> Click here for more funding data on FogPharma >> To export FogPharma funding data to PDF and Excel, click here FogPhar... |
| 02.03.2021 | FogPharma picks up $107M Series C | FogPharma has raised $107 million in a round led by VenBio Partners. Based in the Boston area, the company is a developer of precision medicines designed to target cancer-causing proteins. Founded in 2016, the company was valued at $173.2 m... |
| 02.03.2021 | FogPharma Announces $107M in Series C | CAMBRIDGE, MA, FogPharma, a biopharmaceutical company, announced the company has raised a $107 million Series C financing led by venBio Partners. >> Click here for more funding data on FogPharma >> To export FogPharma fundin... |
| 01.03.2021 | FogPharma :® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform | FogPharma®, a biopharmaceutical company pioneering a new class of precision medicines potentially applicable to all therapeutic targets, including those previously considered “undruggable”, today announced the Company’s $107 million Series ... |
| 01.03.2021 | Daily funding roundup - March 1st, 2021 | Skydio raised $170M; Artiva landed $120M; FogPharma secured $107M; Axonius picks up $100M Skydio: Skydio is a Redwood City, Ca.-based autonomous drone-maker. Skydio has raised $170 million in Series D funding at a post-money valuation of mo... |
| 21.05.2018 | FogPharma Secures $66M Series B | BOSTON, MA, FogPharma today announced the closing of a $66 million Series B financing. >> Click here for more funding data on FogPharma >> To export FogPharma funding data to PDF and Excel, click here FogPharma today anno... |
Show more